Recruiting studies: Pd L1 Gene Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced
NA · 1 location(s) · Wuxi People's Hospital · NCT06430502 Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Phase N/A · 22 location(s) · Fundación GECP · NCT06634199 Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis
Phase 2 · 1 location(s) · Fudan University · NCT06501378 A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · 419 location(s) · Eli Lilly and Company · NCT06119581 Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
Phase N/A · 2 location(s) · Tianjin Medical University · NCT07618936 TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
Phase N/A · 25 location(s) · Antalya Training and Research Hospital · NCT07279402 Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expressi
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT07655622 Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1
Phase 2 · 2 location(s) · Ruijin Hospital · NCT06269211 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
EARLY_Phase 1 · 5 location(s) · Radiopharm Theranostics, Ltd · NCT06305962 Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Phase 2 · 1 location(s) · Fudan University · NCT06501391 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/Phase 2 · 77 location(s) · PMV Pharmaceuticals, Inc · NCT04585750 Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally
Phase N/A · 1 location(s) · Guangdong Association of Clinical Trials · NCT07696832

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.